Orthopedic Surgery

Treatment Strategy: Why Surgery is the Gold Standard

At a Glance

Surgery is the primary treatment for chondrosarcoma because these tumors are highly resistant to standard chemotherapy and radiation. Depending on the tumor's grade and location, surgeons use techniques like bone scraping (curettage) or limb-sparing surgery to remove the cancer safely.

Treatment for chondrosarcoma is highly specialized because this cancer behaves differently than most. Because the tumor is often “brick-like”—hard and resistant to chemical or radiation attacks—the surgeon is usually the primary lead in your care team ^[1]^[2].

The Surgical Strategy: Grade and Location is the Guide

The goal of surgery is to remove the cancer while preserving as much function as possible. The technique your surgeon chooses depends entirely on the grade and location of your tumor ^[3].

Intralesional Curettage (For ACT in the Limbs): For low-grade tumors in the arms and legs (Atypical Cartilaginous Tumors), the surgeon often “scrapes” the tumor out of the hollow part of the bone ^[4]. To ensure any remaining microscopic cells are destroyed, they use local adjuvants like liquid nitrogen (cryotherapy), phenol, or bone cement (which generates heat as it hardens) ^[5]^[6]. This approach preserves the bone’s structure and joint function ^[7].
Wide En Bloc Resection (For Grade 1 in Pelvis/Spine, and all Grade 2 & 3): Tumors in the axial skeleton or higher-grade tumors require a “wide margin” ^[3]. The surgeon removes the tumor in one single piece (en bloc) along with a surrounding cuff of healthy tissue ^[8]. The goal is an R0 Resection, where no cancer cells are visible even under a microscope at the very edge of the removed tissue ^[9].

Will I lose my limb?

While removing a section of bone sounds terrifying, amputations are very rare today. Surgeons typically perform limb-sparing surgery, reconstructing the missing bone using metal implants (endoprostheses) or bone grafts from a donor, allowing you to keep your arm or leg ^[7]^[8].

Treatment Decision Tree

\begin{array}{l} \text{Diagnosis of Chondrosarcoma} \\ \downarrow \\ \text{Determine Grade and Location} \\ \swarrow \hspace{4em} \searrow \\ \textbf{ACT (Limbs)} \hspace{3em} \textbf{Grade 1 (Axial) or Grade 2/3} \\ \downarrow \hspace{6em} \downarrow \\ \text{Curettage + Adjuvants} \hspace{1em} \text{Wide En Bloc Resection} \\ \downarrow \hspace{6em} \downarrow \\ \text{Functional Recovery} \hspace{1em} \text{Reconstruction (Grafts/Implants)} \end{array}

Why Standard Treatments Often Fail

Patients often wonder why they aren’t receiving the “standard” chemotherapy or radiation used for other cancers. There are three biological reasons for this resistance:

Poor Blood Supply: Cartilage tumors have very few blood vessels, making it difficult for chemotherapy drugs to reach the center of the mass ^[2].
Slow Growth: Traditional chemo and radiation target rapidly dividing cells. Most chondrosarcomas grow slowly, allowing them to “ignore” these treatments ^[10].
Pump Mechanisms: Chondrosarcoma cells often overproduce P-glycoprotein, a protein that acts like a “sump pump,” pushing chemotherapy drugs back out of the cell before they can work ^[11]^[12].

Options for Advanced or Resistant Disease

When surgery isn’t enough—such as in metastatic or “dedifferentiated” cases—doctors look toward specialized systemic therapies and clinical trials ^[13].

Targeted IDH Inhibitors: For the 50-70% of patients with an IDH1 mutation, drugs like ivosidenib are being used to “switch off” the abnormal metabolic signals driving the cancer ^[14]^[15].
Tyrosine Kinase Inhibitors (TKIs): Drugs like pazopanib target the tumor’s ability to create new blood vessels and have shown some success in stabilizing advanced disease ^[10].
Immunotherapy: Newer research is exploring immune checkpoint inhibitors (like anti-PD-1 antibodies), which help the body’s own immune system recognize and attack the cancer cells, particularly in aggressive dedifferentiated types ^[16]^[17].
Clinical Trials: Many patients benefit from participating in trials testing CDK4/6 inhibitors or PARP inhibitors, which aim to break the tumor’s natural defenses ^[10]^[18].

Common questions in this guide

Why is surgery the main treatment for chondrosarcoma instead of chemotherapy?

Surgery is the primary treatment because chondrosarcoma tumors are often hard, have poor blood supply, and grow slowly. These factors make them highly resistant to standard chemotherapy and radiation, making surgical removal the most effective way to eliminate the cancer.

Will I lose my limb if I have bone cancer?

Amputations are very rare today. Most patients are candidates for limb-sparing surgery, where the surgeon removes the tumor and reconstructs the missing bone using metal implants or bone grafts to help you keep your arm or leg.

What is intralesional curettage?

Intralesional curettage is a procedure used for low-grade tumors in the arms and legs. The surgeon scrapes the tumor out of the hollow part of the bone and then uses treatments like liquid nitrogen or bone cement to destroy any remaining microscopic cancer cells.

What happens if my tumor requires a wide en bloc resection?

If the tumor is high-grade or located in the pelvis or spine, surgeons typically perform a wide en bloc resection. This involves removing the tumor in one single piece along with a surrounding layer of healthy tissue to ensure no cancer cells are left behind.

What are the treatment options for advanced or resistant chondrosarcoma?

For advanced, metastatic, or resistant cases, doctors may use specialized systemic therapies. These include targeted IDH inhibitors, tyrosine kinase inhibitors that stop new blood vessel growth, immunotherapy, or clinical trials testing new drugs.

Curated prompts to bring to your next appointment.

1.Based on my tumor's grade and location, am I a candidate for intralesional curettage or do I require a wide en bloc resection?
2.If we proceed with curettage, which local adjuvants (like liquid nitrogen or bone cement) will you use to help prevent recurrence?
3.What is the plan for functional reconstruction after the tumor is removed, and will it involve an implant or a bone graft?
4.Has my tumor been tested for IDH1/2 mutations to see if I might qualify for targeted therapy trials if the disease progresses?
5.Given the resistance of this cancer to standard chemotherapy, what is your experience with newer systemic options like tyrosine kinase inhibitors or immunotherapy?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (18)

1
Effect of surgery and radiotherapy on overall survival in patients with chondrosarcoma: A SEER-based study.
Wang M, Song Y, Liu S, Sun W
Journal of orthopaedic surgery (Hong Kong) 2022; (30(1)):10225536221086319 doi:10.1177/10225536221086319.
PMID: 35349776
2
Rare Case of Scapular Body Chondrosarcoma Treated With Limb-Salvage Partial Scapulectomy: A Case Report Highlighting Surgical Technique.
Alfadil S, Alarnous FM, Alsuwayeh F, et al.
Cureus 2024; (16(10)):e71519 doi:10.7759/cureus.71519.
PMID: 39553041
3
Chondrosarcoma.
Weinschenk RC, Wang WL, Lewis VO
The Journal of the American Academy of Orthopaedic Surgeons 2021; (29(13)):553-562 doi:10.5435/JAAOS-D-20-01188.
PMID: 33595238
4
Is intralesional resection suitable for central grade 1 chondrosarcoma: A systematic review and updated meta-analysis.
Chen X, Yu LJ, Peng HM, et al.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017; (43(9)):1718-1726 doi:10.1016/j.ejso.2017.05.022.
PMID: 28666625
5
Long-term follow up of patients with low-grade chondrosarcoma in the appendicular skeleton treated by extended curettage and liquid nitrogen.
El Masry AM, Azmy SI, Mustafa MAR, Abdel Aal MM
Orthopaedics & traumatology, surgery & research : OTSR 2023; (109(3)):103410 doi:10.1016/j.otsr.2022.103410.
PMID: 36116704
6
Case Report: Reconstruction After Anterior Pubic Hemipelvectomy.
Murphy B, Thillainadesan T, Robinson K, et al.
Frontiers in surgery 2021; (8()):585600 doi:10.3389/fsurg.2021.585600.
PMID: 34095198
7
Intralesional curettage of central low-grade chondrosarcoma: A midterm follow-up study.
Chen YC, Wu PK, Chen CF, Chen WM
Journal of the Chinese Medical Association : JCMA 2017; (80(3)):178-182 doi:10.1016/j.jcma.2016.10.002.
PMID: 27889461
8
Chondrosarcoma arising in monostotic fibrous dysplasia treated with total femur resection and megaprothesis: A case report.
Wahyudi M, Alaztha Z
International journal of surgery case reports 2021; (85()):106194 doi:10.1016/j.ijscr.2021.106194.
PMID: 34293652
9
Precision medicine for adjuvant chemotherapy of resected colorectal cancer.
Miyamoto Y, Hiyoshi Y, Sawayama H, et al.
Annals of gastroenterological surgery 2020; (4(6)):635-645 doi:10.1002/ags3.12397.
PMID: 33319153
10
Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target.
Ouyang Z, Wang S, Zeng M, et al.
Cell communication and signaling : CCS 2019; (17(1)):17 doi:10.1186/s12964-019-0327-5.
PMID: 30808351
11
Amphiregulin promotes cisplatin chemoresistance by upregulating ABCB1 expression in human chondrosarcoma.
Huang YW, Lin CY, Tsai HC, et al.
Aging 2020; (12(10)):9475-9488 doi:10.18632/aging.103220.
PMID: 32428872
12
Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines.
Freund SS, Bendtsen MM, Safwat A, Joergensen PH
Journal of cancer research and therapeutics 2023; (19(Supplement)):S278-S284 doi:10.4103/jcrt.JCRT_565_19.
PMID: 37148005
13
Chondrosarcoma-from Molecular Pathology to Novel Therapies.
Zając AE, Kopeć S, Szostakowski B, et al.
Cancers 2021; (13(10)) doi:10.3390/cancers13102390.
PMID: 34069269
14
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
Tap WD, Cote GM, Burris H, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2025; (31(11)):2108-2114 doi:10.1158/1078-0432.CCR-24-4128.
PMID: 40100120
15
Chondrosarcoma: Clinical Behavior, Molecular Mechanisms, and Emerging Therapeutic Strategies.
Agulnik M, Wilky BA, Thorpe Facs SW, Zuckerman LM
Critical reviews in oncology/hematology 2025; 105075 doi:10.1016/j.critrevonc.2025.105075.
PMID: 41391500
16
Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trial.
Li B, Xie L, Liang J, et al.
Med (New York, N.Y.) 2025; (6(11)):100809 doi:10.1016/j.medj.2025.100809.
PMID: 40882625
17
New advances in the treatment of chondrosarcoma under the PD-1/PD-L1 pathway.
Yin J, Ren P
Journal of cancer research and therapeutics 2024; (20(2)):522-530 doi:10.4103/jcrt.jcrt_2269_23.
PMID: 38687921
18
Radiosensitizing Effect of PARP Inhibition on Chondrosarcoma and Chondrocyte Cells Is Dependent on Radiation LET.
Gilbert A, Tudor M, Delaunay A, et al.
Biomolecules 2024; (14(9)) doi:10.3390/biom14091071.
PMID: 39334838

This page explains chondrosarcoma treatment strategies for educational purposes only. Always consult with a specialized orthopedic oncologist to determine the best surgical or systemic treatment plan for your specific tumor.

Get notified when new evidence is published on Chondrosarcoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents